ALA just got 5m in cash and its iNKT - platform gets developed by IMU to get an IND approval. IMU got about 185m and maybe soon more than 200m in cash and got several platforms in clinical trials.
At ALA hardly any cash and just one non - clinical platform sees its sp almost double in a week while IMU gets hammered. Something isn't right. Either cash and IP counts or not. If ALA is a guide to go buy then IMU should really throw its cash and IP away to increase the sp. Sometimes the market makes no sense at all unless ALA gets pumped for a CR. But if that's the case then how could they get a premium for almost nothing while Hopper is discounting IMU for probably the cure for solid cancer and tells us there is no money out there.
GLTA
IMU Price at posting:
6.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)